Free Trial
NASDAQ:PPBT

Purple Biotech (PPBT) Stock Price, News & Analysis

Purple Biotech logo
$2.80 +0.07 (+2.38%)
Closing price 03:57 PM Eastern
Extended Trading
$2.78 -0.02 (-0.72%)
As of 07:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Purple Biotech Stock (NASDAQ:PPBT)

Key Stats

Today's Range
$2.70
$2.93
50-Day Range
$2.38
$3.30
52-Week Range
$2.00
$20.60
Volume
3,789 shs
Average Volume
248,069 shs
Market Capitalization
$3.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.00
Consensus Rating
Buy

Company Overview

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

Purple Biotech Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
28th Percentile Overall Score

PPBT MarketRank™: 

Purple Biotech scored higher than 28% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Purple Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Purple Biotech has received no research coverage in the past 90 days.

  • Read more about Purple Biotech's stock forecast and price target.
  • Earnings Growth

    Earnings for Purple Biotech are expected to decrease in the coming year, from ($0.83) to ($1.65) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Purple Biotech is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Purple Biotech is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Purple Biotech has a P/B Ratio of 0.10. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Purple Biotech's valuation and earnings.
  • Percentage of Shares Shorted

    2.16% of the float of Purple Biotech has been sold short.
  • Short Interest Ratio / Days to Cover

    Purple Biotech has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Purple Biotech has recently increased by 11.35%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Purple Biotech does not currently pay a dividend.

  • Dividend Growth

    Purple Biotech does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.16% of the float of Purple Biotech has been sold short.
  • Short Interest Ratio / Days to Cover

    Purple Biotech has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Purple Biotech has recently increased by 11.35%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Purple Biotech this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Purple Biotech insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.98% of the stock of Purple Biotech is held by insiders.

  • Percentage Held by Institutions

    Only 9.64% of the stock of Purple Biotech is held by institutions.

  • Read more about Purple Biotech's insider trading history.
Receive PPBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Purple Biotech and its competitors with MarketBeat's FREE daily newsletter.

PPBT Stock News Headlines

Purple Biotech announces publication of study on potential of NT219
New “Trump” currency proposed in DC
According to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America.
Purple Biotech reports Q4 EPS (26c) vs. ($3.80) last year
Purple Biotech sees cash runway into mid-2026
See More Headlines

PPBT Stock Analysis - Frequently Asked Questions

Purple Biotech's stock was trading at $4.69 at the start of the year. Since then, PPBT stock has decreased by 40.4% and is now trading at $2.7950.
View the best growth stocks for 2025 here
.

Purple Biotech Ltd (NASDAQ:PPBT) posted its quarterly earnings results on Monday, March, 10th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by $0.04.

Purple Biotech shares reverse split on Tuesday, September 17th 2024. The 1-20 reverse split was announced on Friday, September 13th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Purple Biotech's top institutional shareholders include Kingswood Wealth Advisors LLC (1.26%).

Shares of PPBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Purple Biotech investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Broadcom (AVGO), GE Aerospace (GE), Adobe (ADBE) and Catalyst Pharmaceuticals (CPRX).

Company Calendar

Last Earnings
3/10/2025
Today
4/25/2025
Next Earnings (Estimated)
5/20/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PPBT
Previous Symbol
NASDAQ:KTOV
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$33.00
High Stock Price Target
$33.00
Low Stock Price Target
$33.00
Potential Upside/Downside
+1,080.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-19,880,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$27.18 per share
Price / Book
0.10

Miscellaneous

Free Float
1,291,000
Market Cap
$3.72 million
Optionable
Optionable
Beta
0.62
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:PPBT) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners